Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study
Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study
复制标题
DOI：
10.1136/bjophthalmol-2011-300218
复制
发表时间：
2012-05-01
影响因子：
4.1
通讯作者：
Garcia-Feijoo, Julian
中科院分区：
文献类型：
--
作者：
Arriola-Villalobos, Pedro;Maria Martinez-de-la-Casa, Jose;Garcia-Feijoo, Julian
目的评价白内障手术联合Glaukos iStent植入术治疗开角型青光眼合并白内障的长期疗效和安全性。方法前瞻性、非对照、非随机、干预性病例系列研究。年龄大于18岁的受试者，患有不受控制的轻度或中度开角型青光眼（包括假性剥脱性和色素性青光眼）和白内障，接受了超声乳化和人工透镜植入术沿着在前房角镜引导下植入一个Glaukos iStent。在最少3年的随访中记录的变量是：眼内压（IOP），抗青光眼药物的数量和最佳矫正视力acuity.Results的19例患者的年龄为58-88岁（平均年龄74.6 +/- 8.44岁）。平均随访时间为53.68 ± 9.26个月。随访结束时，平均IOP从19.42 +/- 1.89 mm Hg降至16.26 +/- 4.23 mm Hg（p=0.002），表明IOP降低16.33%。患者使用降压药物的平均数量从1.32 +/- 0.48下降到0.84 +/- 0.89（p=0.046）。42%的患者在随访结束时未使用抗青光眼药物。平均最佳矫正视力从0.29 +/- 0.13显著提高到0.62 +/- 0.3（p
Aims To evaluate the long-term efficacy and safety of combined cataract surgery and Glaukos iStent implantation for coexistent open-angle glaucoma and cataract.Methods Prospective, non-comparative, uncontrolled, non-randomised, interventional case series study. Subjects older than 18 years with coexistent uncontrolled mild or moderate open-angle glaucoma (including pseudoexfoliative and pigmentary) and cataract underwent phacoemulsification and intraocular lens implantation along with ab-interno gonioscopically guided implantation of one Glaukos iStent. The variables recorded during a minimum of 3 years of follow-up were: intraocular pressure (IOP), number of antiglaucoma medications and best-corrected visual acuity.Results The 19 patients enrolled were 58-88 years old (mean age 74.6 +/- 8.44 years). Mean follow-up was 53.68 +/- 9.26 months. Mean IOP was reduced from 19.42 +/- 1.89 mm Hg to 16.26 +/- 4.23 mm Hg (p=0.002) at the end of follow up, indicating a 16.33% decrease in IOP. The mean number of pressure-lowering medications used by the patients fell from 1.32 +/- 0.48 to 0.84 +/- 0.89 (p=0.046). In 42% of patients, no antiglaucoma medications were used at the end of follow-up. Mean best-corrected visual acuity significantly improved from 0.29 +/- 0.13 to 0.62 +/- 0.3 (p